Round Type
Funding Round
FraminghamBiotechnologyDescription
Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it completed a private placement with institutional and accredited individual investors (collectively, the “Investors”) as a Bridge Offering preceding a planned national exchange listing of the Company’s common stock on either Nasdaq Global Market, Nasdaq Capital Market, New York Stock Exchange or NYSE American (the “Uplisting”). The private placement consisted of the issuance of common stock, par value $0.001, at a purchase price of $0.275 per share and accompanying common warrant to purchase two shares of common stock (or pre-funded warrants at a purchase price of $0.274 per pre-funded warrant and accompanying common warrant to purchase two shares of common stock) with total gross proceeds of approximately $2.6 million in the aggregate in connection with two separate closings (the “Bridge Offering”), with the initial closing in July. Lowenstein Sandler LLP acted as counsel to the Company in connection with the Bridge Offering, and ArentFox Schiff LLP served as counsel to Dawson James Securities, Inc.
Quick answer
Arch Therapeutics raised an undisclosed amount in a Funding Round round, dated September 7, 2023. Arch Therapeutics is based in Framingham, Massachusetts, United States.
- How much did Arch Therapeutics raise?
- Arch Therapeutics raised an undisclosed amount in a Funding Round round on September 7, 2023.
- What does Arch Therapeutics do?
- Arch Therapeutics, Inc. (OTCQB:ARTH) is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care.
- Where is Arch Therapeutics based and how big is it?
- Arch Therapeutics is based in Framingham, Massachusetts, United States.
- Who are the decision-makers at Arch Therapeutics?
- Fundz holds 1 contact at Arch Therapeutics, including the Executive Officer, Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Arch Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- VitaTek raised an undisclosed amount (Series A) on October 22, 2023.
- INNOCAN PHARMA Corp raised an undisclosed amount (Funding Round) on October 20, 2023.
- Amatera raised $1.6M (Seed) on October 20, 2023.
- Stramsen BiotechInc raised $10M (Series F) on October 20, 2023.
- Celcuity raised $50M on October 20, 2023.
- Propanc Biopharma raised $40K (Seed) on October 20, 2023.
Who to call at Arch Therapeutics, and when
A new round usually means Arch Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Arch Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Arch Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Arch Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Arch Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Arch Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.